Minocycline in the eradication of Helicobacter pylori infection: A systematic review and meta-analysis

被引:1
作者
Zhou, Kai [1 ]
Li, Cai-Ling [1 ]
Zhang, Hua [1 ]
Suo, Bao-Jun [1 ]
Zhang, Yu-Xin [1 ]
Ren, Xin-Lu [1 ]
Wang, Yu-Xin [1 ]
Mi, Chang-Min [1 ]
Ma, Ling-Ling [1 ]
Zhou, Li-Ya [1 ]
Tian, Xue-Li [1 ]
Song, Zhi-Qiang [1 ]
机构
[1] Peking Univ Third Hosp, Dept Gastroenterol, 49 North Garden Rd, Beijing 100191, Peoples R China
基金
中国国家自然科学基金; 北京市自然科学基金;
关键词
Helicobacter pylori; Minocycline; Eradication; Safety; Resistance; 2ND-LINE REGIMENS; TETRACYCLINE; BISMUTH; 1ST-LINE; METRONIDAZOLE; RESISTANCE; THERAPY; CLARITHROMYCIN; ESOMEPRAZOLE; ANTIBIOTICS;
D O I
10.3748/wjg.v30.i17.2354
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND Difficulty in obtaining tetracycline, increased adverse reactions, and relatively complicated medication methods have limited the clinical application of the classic bismuth quadruple therapy. Therefore, the search for new alternative drugs has become one of the research hotspots. In recent years, minocycline, as a semisynthetic tetracycline, has demonstrated good potential for eradicating Helicobacter pylori (H. pylori) infection, but the systematic evaluation of its role remains lacking. AIM To explore the efficacy, safety, and compliance of minocycline in eradicating H. pylori infection. METHODS We comprehensively retrieved the electronic databases of PubMed, Embase, Web of Science, China National Knowledge Infrastructure, SinoMed, and Wanfang database as of October 30, 2023, and finally included 22 research reports on H. pylori eradication with minocycline-containing regimens as per the inclusion and exclusion criteria. The eradication rates of H. pylori were calculated using a fixed or a random effect model, and the heterogeneity and publication bias of the studies were measured. RESULTS The single-arm meta-analysis revealed that the minocycline-containing regimens achieved good overall H. pylori eradication rates, reaching 82.3% [95% confidence interval (CI): 79.7%-85.1%] in the intention-to-treat analysis and 90.0% (95%CI: 87.7%-92.4%) in the per-protocol analysis. The overall safety and compliance of the minocycline-containing regimens were good, demonstrating an overall incidence of adverse reactions of 36.5% (95%CI: 31.5%-42.2%). Further by traditional meta-analysis, the results showed that the minocycline-containing regimens were not statistically different from other commonly used eradication regimens in eradication rate and incidence of adverse effects. Most of the adverse reactions were mild to moderate and well-tolerated, and dizziness was relatively prominent in the minocycline-containing regimens (16%). CONCLUSION The minocycline-containing regimens demonstrated good efficacy, safety, and compliance in H. pylori eradication. Minocycline has good potential to replace tetracycline for eradicating H. pylori infection.
引用
收藏
页码:2354 / 2368
页数:16
相关论文
共 46 条
  • [1] Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines
    Agwuh, Kenneth N.
    MacGowan, Alasdair
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (02) : 256 - 265
  • [2] Susceptibility of Helicobacter pylori to antibiotics in Chinese patients
    Bai, Peng
    Zhou, Li Ya
    Xiao, Xiu Mei
    Luo, Yang
    Ding, Yu
    [J]. JOURNAL OF DIGESTIVE DISEASES, 2015, 16 (08) : 464 - 470
  • [3] Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection
    Bergeron, J
    Ammirati, M
    Danley, D
    James, L
    Norcia, M
    Retsema, J
    Strick, CA
    Su, WG
    Sutcliffe, J
    Wondrack, L
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (09) : 2226 - 2228
  • [4] ACG Clinical Guideline: Treatment of Helicobacter pylori Infection
    Chey, William D.
    Leontiadis, Grigorios I.
    Howden, Colin W.
    Moss, Steven F.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 (02) : 212 - 239
  • [5] The impact of Helicobacter pylori infection and eradication therapy containing minocycline and metronidazole on intestinal microbiota
    Cui, Meng-Yan
    Cui, Zhen-Yu
    Zhao, Meng-Qi
    Zhang, Meng-Jie
    Jiang, Qiao-Li
    Wang, Jing-Jing
    Lu, Lun-Gen
    Lu, Ying-Ying
    [J]. BMC MICROBIOLOGY, 2022, 22 (01)
  • [6] Emergence of tetracycline resistance in Helicobacter pylori:: Multiple mutational changes in 16S ribosomal DNA and other genetic loci
    Dailidiene, D
    Bertoli, MT
    Miciuleviciene, J
    Mukhopadhyay, AK
    Dailide, G
    Pascasio, MA
    Kupcinskas, L
    Berg, DE
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (12) : 3940 - 3946
  • [8] Tetracycline antibiotics and resistance mechanisms
    Fabian Nguyen
    Starosta, Agata L.
    Arenz, Stefan
    Sohmen, Daniel
    Doenhoefer, Alexandra
    Wilson, Daniel N.
    [J]. BIOLOGICAL CHEMISTRY, 2014, 395 (05) : 559 - 575
  • [9] Efficacy and safety of minocycline quadruple therapy for Helicobacter pylori eradication: A meta-analysis of RCTs
    Gao, Wenwen
    Zhu, Mingliang
    Yin, Yanhui
    Zhang, Xiang
    Wang, Lu
    [J]. HELICOBACTER, 2023, 28 (06)
  • [10] Minocycline: far beyond an antibiotic
    Garrido-Mesa, N.
    Zarzuelo, A.
    Galvez, J.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2013, 169 (02) : 337 - 352